Trial Information
Investigation of Lactate Measured Using Magnetic Resonance Spectroscopy as a Biomarker of Tumour Response
Inclusion Criteria:
Cohort 1:lymphoma patients
- minimum lesion size of 2cm
- not pre-treated but scheduled to be treated with CHOP (Cyclophosphamide,
Hydroxydaunomycin,Oncovin and Prednisilone)
Cohort 2:Colorectal patients
- metastatic disease of at least 2cm
- not pre-treated
Cohort 3:Phase 1 Drug Development
- minimum lesion size at least 2cm
Exclusion Criteria:
- MRI incompatible metal implants
- Claustrophobia
- Inability to tolerate a 40 minute MRI scan
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Correlation between changes in MRS lactate measurements at two time points after treatment and clinical response
Outcome Time Frame:
7 and 21 days post treatment
Safety Issue:
No
Principal Investigator
Nandita deSouza, Professor
Investigator Role:
Principal Investigator
Investigator Affiliation:
ICR
Authority:
United Kingdom: Research Ethics Committee
Study ID:
13/LO/0536 CCR3939
NCT ID:
NCT01881386
Start Date:
July 2013
Completion Date:
Related Keywords:
- Cancer
- Magnetic Resonance Spectroscopy
- Lactate